Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 study
Rui Hua(Southern Medical University), Junqi Niu(Jilin University), Yujuan Guan(Guangzhou Eighth People's Hospital), Chenxin Meng(The Sixth People's Hospital of Shenyang), Qiong Wu(China Pharmaceutical University), Jiefei Wang(CAE (Canada)), Cheng Li(Guangzhou Medical University), Jiayu Chen(East China University of Science and Technology), Zhiqiang Wang(Harbin Normal University), Xian Zhang(China Pharmaceutical University), Guangming Li(The Sixth People's Hospital of Zhengzhou), Yuexin Zhang(University of Houston), Qingfang Xiong(Nanjing Second Hospital), Bin Xu(Beijing Friendship Hospital), Fei Kong(Shanghai Jiao Tong University), Liwen Zhao(China Pharmaceutical University), Youwen Tan(Jiangsu University), Xiaofeng Wen(Liuzhou General Hospital), Hong Ma(Beijing Friendship Hospital), Yan Huang(Central South University), Xiaorong Mao(First Hospital of Lanzhou University), Hainv Gao, Yongfang Jiang(Central South University), Yongning Xin(Qingdao University)
Cited by 7
Related Papers
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome
|The Lancet|2013|839
Psychological impacts and coping strategies of front-line medical staff during COVID-19 outbreak in Hunan, China
|Medical Science Monitor|2020|784
Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection
|New England Journal of Medicine|2013|655
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
|Journal of Clinical Oncology|2011|644